Department of Neurology, University of California, Irvine, CA, USA.
Int J Stroke. 2011 Aug;6(4):315-6. doi: 10.1111/j.1747-4949.2011.00618.x.
The fluoxetine for motor recovery after acute ischemic stroke study was a double blind, placebo-controlled trial examining the effects of fluoxetine in patients five- to 10 days after an ischemic stroke. The study found motor improvement to 90 days poststroke, measured as the change in the Fugl-Meyer score, was significantly greater in the fluoxetine group as compared with the placebo group, and that this finding was significant after adjusting for depression. Patients randomized to fluoxetine also had less disability (modified Rankin Scale 0-2). The study adds to the weight of data suggesting that viable strategies exist to improve patient outcomes by initiating a restorative agent, days after stroke injury is fixed. Stroke remains among the leading causes of human disability. Currently, a minority of patients can access approved reperfusion therapies, and among those so treated a substantial fraction derives limited benefit. Therapies that target restorative events have a time window measured in days-weeks and so hold the potential to help many patients with stroke.
氟西汀治疗急性缺血性脑卒中后运动功能恢复的研究是一项双盲、安慰剂对照试验，旨在观察氟西汀对缺血性脑卒中后 5-10 天患者的影响。研究发现，与安慰剂组相比，氟西汀组在脑卒中后 90 天的运动功能改善更明显，在调整抑郁因素后，这一发现具有统计学意义。随机分配到氟西汀组的患者残疾程度（改良 Rankin 量表 0-2）也较低。这项研究增加了数据的权重，表明通过在脑卒中损伤固定后几天开始使用恢复性药物，可以为患者带来更好的预后。脑卒中仍然是导致人类残疾的主要原因之一。目前，只有少数患者可以获得批准的再灌注治疗，而在这些接受治疗的患者中，很大一部分患者获益有限。针对恢复性事件的治疗方法有一个以天-周为单位的时间窗，因此有可能帮助许多脑卒中患者。
